Mylan, King Pharmaceuticals Deal Unlikely
109550
Mylan Laboratories Inc.MYL.N on  Wednesday said it was unlikely to complete its $3.4 billion  acquisition of King Pharmaceuticals Inc.KG.N at the current  price because of King's need to restate earnings.
619694
ASTRAZENECAâS anti-clotting drug Exanta is unlikely to win US approval in the near future, the company said as it revealed a delay with another new drug, Galida for diabetes.
140996
A day late and possibly several millions of dollars short. That's the scenario facing one drug manufacturer unless it can get a helping hand from Congress.
664157
Financier Carl Icahn on Friday offered to buy the shares of generic drugmaker Mylan Laboratories that he does not already own for $4.9 billion, or $20 a share, according to a government filing.
639924
Mylan Laboratories Inc.'s  board on Monday rebuffed financier Carl Icahn's bid to buy the company, and said it remains committed to its &#36;3.37 billion purchase of brand-name drug-maker King Pharmaceuticals Inc. .
476487
The board of Mylan Laboratories rebuffed the financier Carl C. Icahn&#39;s bid to buy the company yesterday, saying it remained committed to acquiring the brand-name drug maker King Pharmaceuticals.
638956
AstraZeneca Plc  is convinced  it can prevail in U.S. patent disputes over its two biggest  drugs, Nexium and Seroquel, and has had no discussions about  settling the cases, its chief executive said on Wednesday.
331749
Not buying it. Megafinancier Carl Icahn has made it clear: He&#39;s still opposed to Mylan Laboratories&#39; (nyse: MYL - news - people ) proposed acquisition of King Pharmaceuticals (nyse: KG - news - people ). Despite
734267
By Thomas Ginsberg, The Philadelphia Inquirer  Jan. 31--Here is something you may not hear every day: The drug giant Wyeth said yesterday that it was "surprised" to hear that it is about to face generic competition on its $216 million heart drug Inderal LA.
60257
Mylan Laboratories Inc. MYL.N, which  is trying to acquire King Pharmaceuticals Inc. KG.N, on  Thursday reported its quarterly profit fell by almost 60  percent on a product delay and fierce competition, and it cut  its 2005 forecast.
363785
Sales of the multiple sclerosis drug are picking up, but probably can't grow into the stock's valuation.
662939
TD AMERITRADE has an urge to merge, but that alone may not make it happen.
609796
Despite concerns raised by an investor, Mylan Laboratories Inc. reaffirmed that its proposed acquisition of generic drug maker King Pharmaceuticals Inc.
543076
Financier Carl Icahn said Monday King Pharmaceutical Inc.&#39;s possible need to restate earnings reinforces his belief that an acquisition of King by Mylan Laboratories Inc.
292602
Drugmaker Mylan Laboratories Inc.  posted a quarterly loss on Thursday on charges related to an acquisition, but reported adjusted profit that beat its previous forecast helped by sales of generic drugs for pain and bladder control.
768370
Billionaire investor Carl Icahn yesterday offered to purchase Mylan Laboratories for $20 per share, part of his plan to derail the Canonsburg generic drug maker&#39;s proposed acquisition of King Pharmaceuticals.
723657
Could a jointly marketed drug lead to a joint company? Ireland&#39;s Sunday Tribune said yesterday that US pharmaceuticals company Biogen Idec (nasdaq: BIIB - news - people ) was looking to make an all-stock bid